Literature DB >> 8194914

Chlamydia pneumoniae IgG antibody prevalence in south-western and eastern Finland in 1982 and 1987.

M Karvonen1, J Tuomilehto, J Pitkäniemi, A Naukkarinen, P Saikku.   

Abstract

Chlamydia pneumonia IgG antibody prevalence was examined in a representative sample (2342 subjects) of the population aged 25-59 years in south-western and eastern Finland in 1982 and 1987. Microimmunofluorescence was used to measure IgG antibodies. Prevalence of C. pneumoniae was modelled using the GLIM statistical package assuming that the prevalence had a binomial distribution. The prevalence was assumed to be a function of the year, subjects' gender, age and place of residence. The effect of the year on the prevalence was significant in both regions (P < 0.05 in the south-west and P < 0.001 in the east). In each year the prevalence was higher in the south-west than in the east and it increased between 1982 and 1987 from 55% to 63% in the south-west and from 41% to 59% in the east. The prevalence increased with age, but the age-related antibody pattern was different between sexes. The highest prevalence was found in men aged 49-59 years. The different increase in prevalence with age in the south-western and the eastern parts of the country indicates that the outbreaks of infection were not related. The endemic level of C. pneumoniae infection in the south-west is consistently higher than in the east, or there was an outbreak of C. pneumoniae infection in both the years we examined. Thus it is more likely that the high prevalence in south-western Finland was connected more with the epidemics reported elsewhere in Scandinavia in the same years than with the occurrence of C. pneumoniae infection in eastern Finland.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194914     DOI: 10.1093/ije/23.1.176

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  8 in total

1.  Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.

Authors:  S Bas; P Muzzin; B Ninet; J E Bornand; C Scieux; T L Vischer
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Chlamydia trachomatis serology: diagnostic value of outer membrane protein 2 compared with that of other antigens.

Authors:  S Bas; P Muzzin; T L Vischer
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

3.  Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays.

Authors:  T Tuuminen; S Varjo; H Ingman; T Weber; J Oksi; M Viljanen
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

4.  A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren.

Authors:  G Dal Molin; B Longo; T Not; A Poli; C Campello
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

Review 5.  Chlamydia pneumoniae and atherosclerosis.

Authors:  Y K Wong; P J Gallagher; M E Ward
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

6.  Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease.

Authors:  Anil Palikhe; Marja-Liisa Lokki; Pekka Saikku; Maija Leinonen; Mika Paldanius; Mikko Seppänen; Ville Valtonen; Markku S Nieminen; Juha Sinisalo
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

7.  Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey.

Authors:  M Gencay; D Dereli; E Ertem; D Serter; M Puolakkainen; P Saikku; B Boydak; S Dereli; B Ozbakkaloglu; A Yorgancioglu; E Tez
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

8.  The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection.

Authors:  Kenichi Shimada; Shuang Chen; Paul W Dempsey; Rosalinda Sorrentino; Randa Alsabeh; Anatoly V Slepenkin; Ellena Peterson; Terence M Doherty; David Underhill; Timothy R Crother; Moshe Arditi
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.